Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.42 - $138.81
Previous CloseN/A
Volume185.86K
Average Volume (3M)7.54M
Market Cap
$2.18B
Enterprise Value$2.38B
Total Cash (Recent Filing)$800.14M
Total Debt (Recent Filing)$1.35B
Price to Earnings (P/E)19.6
Beta0.76
Next Earnings
Oct 29, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding97,713,440
10 Day Avg. Volume6,730,342
30 Day Avg. Volume7,542,751
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue0.96
Enterprise Value/Gross Profit1.21
Enterprise Value/Ebitda54.06
Forecast
1Y Price Target
$22.83Price Target Upside0.84% Upside
Rating ConsensusHold
Number of Analyst Covering26
Bulls Say, Bears Say
Bulls Say
DiversificationDM1/FHSD readouts could diversify SRPT's business, attracting new investors.
Market ConfidenceThe physician survey indicates that a majority of physicians continue to prescribe Elevidys, even after patient deaths, suggesting strong market confidence.
Bears Say
Operational ChallengesSarepta Therapeutics pulled its revenue guidance for the fiscal year 2025 and halted enrollment and dosing in the non-ambulatory confirmatory ENVISION trial.
Regulatory RiskThe potential death of an ambulatory Elevidys patient remains the biggest risk, which could trigger concerns about the market removal of Elevidys.
Safety ConcernsConcerns surrounding Elevidys' uptake due to several safety signals keep the analyst on the sidelines regarding Sarepta's stock.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $10.41 and its highest was $138.81 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $2.18B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is in 24 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 06, 2025. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $0.832 by $1.058.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -0.64.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 97,713,440 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $1.89 in its last earnings report, beating expectations of $0.832. Following the earnings report the stock price went up 10.455%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.83 (0.84% Upside)
$22.83 (0.84% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 62%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.93%
12-Months-Change
Fundamentals
Return on Equity
-4.76%
Trailing 12-Months
Asset Growth
7.46%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic restructuring, cost-saving measures, and a focused pipeline to strengthen Sarepta's financial position and future growth. However, challenges such as workforce reduction, hesitancy in ELEVIDYS adoption, and suspension of nonambulatory ELEVIDYS shipments present significant hurdles.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$22.83
▲(0.84% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
4.68% Insiders
17.61% Mutual Funds
21.78% Other Institutional Investors
28.48% Public Companies and Individual Investors